Modality
siRNA
MOA
PARPi
Target
TYK2
Pathway
JAK/STAT
Huntington'sT2D
Development Pipeline
Preclinical
~Sep 2012
→ ~Dec 2013
Phase 1
~Mar 2014
→ ~Jun 2015
Phase 2
~Sep 2015
→ ~Dec 2016
Phase 3
Mar 2017
→ Jul 2027
Phase 3Current
NCT03600715
1,906 pts·T2D
2017-03→2027-06·Terminated
NCT04313123
282 pts·Huntington's
2023-01→2026-05·Active
NCT06393879
2,845 pts·T2D
2018-02→2027-07·Recruiting
5,033 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-05-121mo awayPh3 Readout· Huntington's
2027-06-051.2y awayPh3 Readout· T2D
2027-07-161.3y awayPh3 Readout· T2D
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P3
Termina…
P3
Recruit…
P3
Active
Catalysts
Ph3 Readout
2026-05-12 · 1mo away
Huntington's
Ph3 Readout
2027-06-05 · 1.2y away
T2D
Ph3 Readout
2027-07-16 · 1.3y away
T2D
RecruitingActiveTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03600715 | Phase 3 | T2D | Terminated | 1906 | HAM-D |
| NCT04313123 | Phase 3 | Huntington's | Active | 282 | NT-proBNP |
| NCT06393879 | Phase 3 | T2D | Recruiting | 2845 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |